Drug intelligence / Profile preview

RapVac-2201

Development stage: Preclinical
Lead developer: RAPHAS
Modality: Vaccines & Immunotherapeutics
Administration: Percutaneous, Intradermal

Overview

RapVac-2201 is a preclinical-stage vaccine candidate being developed by RAPHAS for the prevention of tuberculosis, specifically as a booster vaccine. It utilizes RAPHAS's proprietary dissolving microneedle (DMN) technology, which allows for the stable delivery of vaccine antigens through the skin. The vaccine is designed to stimulate protective immunity against *Mycobacterium tuberculosis*. By employing a microneedle patch modality, RapVac-2201 aims to provide a more convenient, pain-free, and potentially more effective alternative to traditional injectable vaccines, while also offering advantages in terms of storage and distribution due to the stability of the microneedle formulation.

Other names: RapVac-2201RapVac2201RapVac 2201

Beyond the preview

Go deeper on RapVac-2201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RapVac-2201.

Explore the full profile